Follow the news, literature, and elearning on new developments in the management of Heart Failure.
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
In HFrEF patients with an ICD under remote control, treatment with ARNI decreased ventricular arrhythmias and appropriate ICD shocks as compared to angiotensin inhibition alone.
In heart failure patients with a reduced EF, paroxysmal AF and new onset AF were associated with a greater risk of adverse outcomes, including HF hospitalization and stroke, but not mortality.
In an analysis of the TITRATION study, the majority of patients with low screening SBP tolerated the initiation/up-titration to target dose level of sacubitril/valsartan using a gradual up-titration regimen.
AHA 2017 Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.
In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.
In patients with HFpEF, a higher baseline resting HR and time-updated HR and an increase in resting HR over time since the preceding clinic visit were independently associated with an elevated risk for CV events.
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017
a concentration of 400 pg/mL, any given concentration of NT-proBNP had a similar predictive value for adverse outcomes in HFrEF patients with and without AF.
In the ESC-HF-LT Registry, substantial differences in outcomes were found when patients were stratified by clinical profile, SBP, or congestion/hypo-perfusion phenotypes.
Eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity.
Many T2DM patients with established CVD and without HF are at high or very high risk for HF outcomes. Empagliflozin reduced adverse HF outcomes both in patients at low or high HF risk.